Interview: What Does Breakthrough Designation Mean For Manus Neurodynamica?
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.
You may also be interested in...
Kfir Oved, co-founder and CTO of MeMed, talked to Medtech Insight about diagnostic testing that can differentiate bacterial and viral infections to fight antimicrobial resistance.
A panel of experts in the health care and medical device industries discussed the fate of the Medicare Coverage for Innovative Technology (MCIT) rule during AdvaMed’s annual Medtech Conference.
Manus Neurodynamica intends to launch a pen, which provides early and accurate diagnosis of Parkinson’s disease, to the UK and Benelux markets and has £5m in funding to date.